Skip to main content
SpringerLink
Log in

Introduction

  • Chapter
  • First Online:
Plasma Cell Neoplasms

  • 389 Accesses

Abstract

This chapter provides an overview of the plasma cell neoplasms and covers the 2008 (fourth edition) World Health Organization classification, definition, and epidemiology of plasma cell neoplasms. The chapter also covers the updated International Myeloma Working Group criteria for the diagnosis of multiple myeloma, likely to be featured in the upcoming update to the fourth edition of the WHO classification.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.

    Article  PubMed  Google Scholar 

  2. Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009;113:5412–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood. 2009;113:5418–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Kyle RA, Buadi F, Rajkumar SV. Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Oncology (Williston Park, NY) 2011;25:578–86.

    Google Scholar 

  5. Landgren O, Weiss BM. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. Leukemia. 2009;23:1691–7.

    Article  CAS  PubMed  Google Scholar 

  6. Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. New Engl J Med. 2007;356:2582–90.

    Article  CAS  PubMed  Google Scholar 

  7. Caers J, Fernandez de Larrea C, Leleu X, et al. The changing landscape of smoldering multiple myeloma: a European perspective. Oncologist. 2016;21:333–42.

    Article  CAS  PubMed  Google Scholar 

  8. Schaar CG, Kluin-Nelemans JC, le Cessie S, Franck PF, te Marvelde MC, Wijermans PW. Early response to therapy and survival in multiple myeloma. Br J Haematol. 2004;125:162–6.

    Article  CAS  PubMed  Google Scholar 

  9. Shah J, Blade J, Sonneveld P, et al. Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression. Cancer. 2011;117:3758–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.

    Google Scholar 

  11. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564–9.

    Article  PubMed  Google Scholar 

  12. Cesana C, Klersy C, Barbarano L, et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol: Off J Am Soc Clin Oncol. 2002;20:1625–34.

    Article  Google Scholar 

  13. Montoto S, Blade J, Montserrat E. Monoclonal gammopathy of undetermined significance. New Engl J Med. 2002;346:2087–8; author reply-8.

    Google Scholar 

  14. Garcia-Sanz R, Orfao A, Gonzalez M, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood. 1999;93:1032–7.

    CAS  PubMed  Google Scholar 

  15. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–48.

    Article  PubMed  Google Scholar 

  16. Criteria for the classification of monoclonal gammopathies. multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749–57.

    Article  Google Scholar 

  17. Alexiou C, Kau RJ, Dietzfelbinger H, et al. Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts. Cancer. 1999;85:2305–14.

    Article  CAS  PubMed  Google Scholar 

  18. Dimopoulos MA, Moulopoulos LA, Maniatis A, Alexanian R. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood. 2000;96:2037–44.

    CAS  PubMed  Google Scholar 

  19. Wilder RB, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R. Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone. Cancer. 2002;94:1532–7.

    Article  CAS  PubMed  Google Scholar 

  20. Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol: Off J Am Soc Clin Oncol. 2011;29:1924–33.

    Article  Google Scholar 

  21. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32:45–59.

    CAS  PubMed  Google Scholar 

  22. Gertz MA. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment. Am J Hematol. 2014;89:1132–40.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology and Immunology, Baylor College of Medicine, 1502 Taub Loop—702, Houston, TX, 77030, USA

    Marwan Yared

  2. Department of Pathology and Laboratory Medicine, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, 3333 Burnet Ave., ML 1035, Cincinnati, OH, 45229, USA

    Robert B. Lorsbach

Authors
  1. Marwan Yared
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert B. Lorsbach
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marwan Yared .

Editor information

Editors and Affiliations

  1. for Medical Sciences, University of Arkansas for Medical Sciences, LITTLE ROCK, Arkansas, USA

    Robert B. Lorsbach

  2. Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA

    Marwan Yared

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Yared, M., Lorsbach, R.B. (2016). Introduction. In: Lorsbach, R., Yared, M. (eds) Plasma Cell Neoplasms. Springer, Cham. https://doi.org/10.1007/978-3-319-42370-8_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-42370-8_1

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-42368-5

  • Online ISBN: 978-3-319-42370-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation